«Retabolil" is shown at asthenia, extreme exhaustion, muscular dystrophy, spinal amyotrophy Werdnig-Hoffmann.Also, the drug used in the treatment of osteoporosis, glomerulonephritis, diabetic retinopathy, cancer of the breast.In addition, "Retabolil" is used in the treatment of protein loss caused by complex burns, radiation therapy, trauma, surgery, infection diseases.
«Retabolil" is available as a solution for injection.Injections should be made intramuscularly, introducing the drug as deeply as possible into the gluteal muscle.The period of treatment is individual.The course lasts for several months, sometimes up to 1 year.4 weeks after treatment, if necessary, may be appointed as a second course.
Adults "Retabolil" administered every 3
-4 weeks.The dosage is 25-50 mg.If myopathy amount of the drug is determined individually, depending on the severity of the condition.Persons suffering from severe renal failure, appointed 50 mg "Retabolil" 1 times a week.Children drug is administered at the rate of 0.4 mg / kg body weight 1 time in 3-4 weeks.
dose for cancer patients is 50 mg every 5 days.In severe conditions of dosage and frequency of use of the drug may be increased in accordance with the doctor's recommendations.In particular, anemia, breast carcinoma dose "Retabolilum" can be increased to 200 mg for women and 100 mg for women.The frequency of administration - 1 time per week.
Among the side effects that occur during therapy "Retabolilom" there are vomiting, nausea, burning sensation in the mouth, loss of appetite, acne, edema, hypercalcemia.Possible changes in the sexual and hormonal areas.In the treatment of adolescents to premature cessation of growth.
Treatment "Retabolilom" should not be done for prostate and breast cancer in women, prostate in acute and chronic forms of nephrotic syndrome.The drug is contraindicated in lactating and pregnant women, persons with hypersensitivity to the components of the means.With great care treatment is carried out in patients with lesions of the liver and kidneys, and liver metastases in cancer patients.